HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Journal of Clinical Pathology

• Publication date

  1992-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/jcp.45.8.726PMID 1357006PMCID PMC495156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

  1990cited by this paper
• Oncoprotein stability after tumour resection.

  1990cited by this paper
• Expression of the p185 encoded by her2 oncogene in normal and transformed human tissues

  1990cited by this paper
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

  1990cited by this paper
• c‐erbB‐2 oncoprotein expression in primary human tumors

  1990cited by this paper
• Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance

  1989cited by this paper
• An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.

  1989cited by this paper
• Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon.

  1989cited by this paper
• Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.

  1988cited by this paper
• Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

  1986cited by this paper

• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• Title Page Title: Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer

  2020cites this paper
• Allosteric autoactivation of SOS and its kinetic mechanism

  2019cites this paper
• In situ analysis of Her2 DNA and RNA in retinoblastoma and adjacent retina

  2019cites this paper
• Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH

  2018cites this paper
• Study of Her 2 / Neu Expression in Colon Adenocarcinoma and Its Correlation with Clinicopathological Variables

  2016cites this paper
• HER2/ERBB2 immunoreactivity in human retinoblastoma

  2016cites this paper
• Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.

  2016cites this paper
• CYTOPLASMIC EXPRESSION OF HER2 IN GASTRIC ADENOCARCINOMA: AN UNUSUAL FINDING

  2016cites this paper
• Characterization of HER 2 gene / protein and Ki 67 protein expressions in colorectal carcinoma variants with relation to clinicopathological parameters and prognosis : An immunohistochemical and fluorescence in situ hybridization study

  2015cites this paper
• Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer

  2013cites this paper
• The Relationship Between the Stromal Mast Cell number, Microvessel Density, C-erbB-2 Staining and Survival and Prognostic Factors in Colorectal Carcinoma Kolorektal Adenokarsinomlarda Stromal Mast Hücre Sayisi, Mikrodamar Yoğunluğu ve C-erbB-2 Boyanmasinin Sağkalim ve Prognostik Faktörler ile İlişki

  2012cites this paper
• EVALUATION OF EXPRESSION OF EGFR, HER-2 AND COX-2 IN COLORECTAL CANCER

  2012cites this paper
• The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma.

  2012cites this paper
• Original Article Evaluation of Expression of EGFR, HER-2 and COX-2 in Colorectal Cancer

  2012cites this paper
• Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.

  2009cites this paper
• Human epidermal growth factor receptor-2 family in colorectal adenocarcinoma: correlation with survival and clinicopathological findings

  2009cites this paper
• A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu

  2009cites this paper
• Clinicopathologic Significance of EGFR and Her‐2/neu in Colorectal Adenocarcinomas

  2006cites this paper
• Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti‐EGFR therapy?

  2005cites this paper
• Theneu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas

  2005cites this paper
• Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.

  2005cites this paper
• Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

  2004cites this paper
• Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival.

  2004cites this paper
• HER 2/neu expression and gene amplification in colon cancer

  2003cites this paper
• Role of Growth Factors and Biological Response Modifiers in Lung, Head and Neck and Gastrointestinal Tumors

  2003cites this paper
• Immunohistochemical Study of c-erbB-2 Protein in Colorectal Cancer and the Correlation with Patient Survival

  1998cites this paper
• Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention.

  1998cites this paper
• C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.

  1996cites this paper
• Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma.

  1995cites this paper
• c‐erbB‐2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma

  1995cites this paper
• The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2, (βHCG immunohistochemistry in advanced colorectal cancer

  1995cites this paper
• DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer.

  1995cites this paper
• The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.

  1995cites this paper
• C-erbB-2 immunostaining: problems with interpretation.

  1994cites this paper